Keyphrases
Tumour Necrosis Factor Inhibitor (TNFi)
66%
Sex Differences
66%
Scientific Networks
66%
Axial Spondyloarthritis (AxSpA)
66%
Spondyloarthritis
66%
Randomized Clinical Trial
66%
COVID-19
66%
Clinical Analysis
66%
Booster Vaccination
66%
Relative Risk
66%
Systematic Meta-analysis
66%
Disease Presentation
33%
Treatment Drugs
33%
Cohort-based
33%
Treatment Response
33%
Psoriatic Arthritis
33%
Heterologous Booster
33%
Drug Retention
33%
Female Sex
33%
Observational Cohort Study
33%
Real-world Clinical Practice
33%
Conflicting Results
33%
Physical Function
33%
Non-serious
33%
Serious Adverse Events
33%
All-cause Mortality
22%
Quality of Life
22%
Severe Coronavirus Disease 2019
22%
Adverse Events
22%
Laboratory Confirmation
22%
Vaccine Platform
22%
Risk of Bias
22%
Immunocompromised Status
11%
Valency
11%
Heterologous Booster Vaccine
11%
Homologous Booster
11%
Z-curve
11%
Subgroup Analysis
11%
Current Sampling
11%
GRADE Approach
11%
Meta-analysis
11%
Extracted Data
11%
Safety Outcomes
11%
Cochrane
11%
Booster Vaccine
11%
Outcome Quality
11%
Vaccination Strategy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Spondylarthritis
66%
Adverse Event
66%
Tumor Necrosis Factor Inhibitor
66%
Coronavirinae
66%
Vaccination Policy
66%
Randomized Clinical Trial
66%
Psoriatic Arthritis
33%
Cohort Study
33%
All Cause Mortality
26%
Randomized Controlled Trial
13%
